{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"PyramIDH","nct_id":"NCT06465953","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pyramidh-nct06465953. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PyramIDH","arms":[{"description":null,"label":"Ivosidenib monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Azacitidine monotherapy","type":"EXPERIMENTAL"}],"collaborators":["Servier Bio-Innovation LLC"],"completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"conditions":["Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)","Myelodysplastic Syndromes (MDS)"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivosidenib","otherNames":[],"type":"DRUG"},{"name":"Azacitidine","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"Institut de Recherches Internationales Servier","official_title":"A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants achieving CR and PR by 4 months","timeFrame":"Through 4 months after starting treatment"}],"references":[],"start_date":{"date":"2024-12-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","url":"https://clinicaltrials.gov/study/NCT06465953"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pyramidh-nct06465953"}